Thompson Siegel & Walmsley LLC Has $40.27 Million Position in Biogen Inc. $BIIB

Thompson Siegel & Walmsley LLC lessened its stake in Biogen Inc. (NASDAQ:BIIB) by 25.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 228,807 shares of the biotechnology company’s stock after selling 77,635 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Biogen were worth $40,268,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BIIB. WPG Advisers LLC lifted its stake in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the period. Accredited Wealth Management LLC lifted its position in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares during the period. First Horizon Corp bought a new stake in shares of Biogen in the 4th quarter valued at $30,000. WFA of San Diego LLC acquired a new stake in shares of Biogen during the second quarter worth $32,000. Finally, GoalVest Advisory LLC bought a new position in Biogen during the fourth quarter worth $35,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. lifted their target price on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Truist Financial cut their price target on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a report on Monday, April 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus price target of $215.81.

Biogen Stock Performance

Shares of Biogen stock opened at $196.00 on Monday. The stock has a fifty day simple moving average of $186.66 and a 200 day simple moving average of $182.40. The company has a market capitalization of $28.94 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 1.73 and a beta of 0.20. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the firm earned $3.02 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.